Antimicrobial resistance in gram-positive bacteria.

Gram-positive bacteria are common causes of bloodstream and other infections in hospitalized patients in the United States, and the percentage of nosocomial bloodstream infections caused by antibiotic-resistant gram-positive bacteria is increasing. Methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) are of particular concern. In the United States, approximately 60% of staphylococcal infections in the intensive care unit are now caused by MRSA, and percentages continue to rise. Outbreaks of hospital-acquired MRSA (HA-MRSA) are typically the result of clonal spread by MRSA being transferred from patient to patient, frequently using healthcare personnel as intermediaries. HA-MRSA strains are generally multidrug resistant. Vancomycin is the standard treatment for serious MRSA infections, but a few cases of vancomycin-resistant S aureus (VRSA) have recently emerged in the United States. Community-acquired MRSA (CA-MRSA) is also increasing. Soft tissue infections are the most frequent presentations of CA-MRSA, but life-threatening invasive infections occur as well, including necrotizing pneumonia. The mechanisms of methicillin resistance are the same for CA-MRSA and HA-MRSA, but susceptibilities to non-â-lactam antibiotics often differ. CA-MRSA exhibits broader antibiotic susceptibility than does HA-MRSA. The proportion of enterococci resistant to vancomycin continues to rise in the hospital setting, with the overwhelming majority of infections due to Enterococcus faecium. Clonal spread of VRE has been documented, but polyclonal outbreaks associated with antimicrobial use are also common. The relations between antibiotic use and VRE colonization are complex and related to the antienterococcal activity, biliary excretion, and antianaerobic activity of the antibiotic. Recent results show a decline in invasive pneumococcal disease (IPD) since the introduction of 7-valent pneumococcal conjugate vaccine, and suggest that, where available, vaccines may be useful in the battle to slow the spread of resistant gram-positive cocci.

[1]  L. Rice,et al.  β-Lactam Antibiotics and Gastrointestinal Colonization with Vancomycin-Resistant Enterococci , 2004 .

[2]  W J Martone,et al.  Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991. , 1992, Infection control and hospital epidemiology.

[3]  D. Gerding,et al.  Is there a relationship between vancomycin-resistant enterococcal infection and Clostridium difficile infection? , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  F. Vandenesch,et al.  Community-Acquired Methicillin-Resistant Staphylococcus aureus Carrying Panton-Valentine Leukocidin Genes: Worldwide Emergence , 2003, Emerging infectious diseases.

[5]  M. Gilchrist,et al.  Recommendations for Preventing the Spread of Vancomycin Resistance , 1995, Infection Control & Hospital Epidemiology.

[6]  J. Karlowsky,et al.  Prevalence and antimicrobial susceptibilities of bacteria isolated from blood cultures of hospitalized patients in the United States in 2002 , 2004, Annals of Clinical Microbiology and Antimicrobials.

[7]  R N Jones,et al.  Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  P. M. Terry,et al.  Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus. , 1991, The Journal of infectious diseases.

[9]  B. Cookson,et al.  A new UK strain of epidemic methicillin-resistant Staphylococcus aureus (EMRSA-17) resistant to multiple antibiotics. , 2002, The Journal of antimicrobial chemotherapy.

[10]  J. Jui,et al.  Community-acquired methicillin-resistant Staphylococcus aureus endocarditis in the Detroit Medical Center. , 1982, Annals of internal medicine.

[11]  E. Buescher Community-acquired methicillin-resistant Staphylococcus aureus in pediatrics , 2005, Current opinion in pediatrics.

[12]  F. Claverie-Martin,et al.  Glycopeptide resistance in enterococci. , 2000, International microbiology : the official journal of the Spanish Society for Microbiology.

[13]  J. Carney,et al.  Methicillin-resistant Staphylococcus aureus in a high school wrestling team and the surrounding community. , 1998, Archives of internal medicine.

[14]  Elaine Larson,et al.  Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). , 1995, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[15]  Y. Carmeli,et al.  Fluoroquinolones and the Risk for Methicillin-resistant Staphylococcus aureus in Hospitalized Patients , 2003, Emerging infectious diseases.

[16]  F. Tenover,et al.  Cell Wall Thickening Is a Common Feature of Vancomycin Resistance in Staphylococcus aureus , 2003, Journal of Clinical Microbiology.

[17]  R. Carey,et al.  Staphylococcus aureus with reduced susceptibility to vancomycin--Illinois, 1999. , 2000, MMWR. Morbidity and mortality weekly report.

[18]  J. Morris,et al.  Enterococci Resistant to Multiple Antimicrobial Agents, Including Vancomycin: Establishment of Endemicity in a University Medical Center , 1995, Annals of Internal Medicine.

[19]  S. Kaplan,et al.  Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. , 2004, Pediatrics.

[20]  W. Schaffner,et al.  Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in tennessee after introduction of the pneumococcal conjugate vaccine. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  R. Daum,et al.  Severe Staphylococcus aureus infections caused by clonally related community-acquired methicillin-susceptible and methicillin-resistant isolates. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  R. Wenzel,et al.  Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities , 2003, The Pediatric infectious disease journal.

[23]  C. Whitney,et al.  Vaccines as tools against resistance: the example of pneumococcal conjugate vaccine. , 2004, Seminars in pediatric infectious diseases.

[24]  A. Tomasz,et al.  Secrets of success of a human pathogen: molecular evolution of pandemic clones of meticillin-resistant Staphylococcus aureus. , 2002, The Lancet. Infectious diseases.

[25]  A. Schuchat,et al.  Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era. , 2001, JAMA.

[26]  J. Boyce,et al.  Outbreak of multidrug-resistant Enterococcus faecium with transferable vanB class vancomycin resistance , 1994, Journal of clinical microbiology.

[27]  F. Tenover,et al.  Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. , 1997, The Journal of antimicrobial chemotherapy.

[28]  B. Robinson-Dunn,et al.  Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. , 1999, The New England journal of medicine.

[29]  L. Rice,et al.  Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. , 2000, The New England journal of medicine.

[30]  E. Palavecino Community-acquired methicillin-resistant Staphylococcus aureus infections. , 2004, Clinics in laboratory medicine.

[31]  T. Yokota,et al.  Role of an altered penicillin-binding protein in methicillin- and cephem-resistant Staphylococcus aureus , 1985, Antimicrobial Agents and Chemotherapy.

[32]  H. Neu,et al.  The Crisis in Antibiotic Resistance , 1992, Science.

[33]  Fred C Tenover,et al.  Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. , 2003, The New England journal of medicine.

[34]  J. Shetty,et al.  Genetic Analysis of a High-Level Vancomycin-Resistant Isolate of Staphylococcus aureus , 2003, Science.

[35]  L. Rice,et al.  A polyclonal outbreak of predominantly VanB vancomycin-resistant enterococci in northeast Ohio. Northeast Ohio Vancomycin-Resistant Enterococcus Surveillance Program. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  D. Hospenthal,et al.  Natural history of community-acquired methicillin-resistant Staphylococcus aureus colonization and infection in soldiers. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  L. Saravolatz,et al.  Community-acquired methicillin-resistant Staphylococcus aureus infections: a new source for nosocomial outbreaks. , 1982, Annals of internal medicine.

[38]  Carlene A. Muto,et al.  SHEA Guideline for Preventing Nosocomial Transmission of Multidrug-Resistant Strains of Staphylococcus aureus and Enterococcus , 2003, Infection Control & Hospital Epidemiology.

[39]  C. Walsh,et al.  The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA) , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[40]  D. Elston Community-acquired methicillin-resistant Staphylococcus aureus. , 2007, Journal of the American Academy of Dermatology.

[41]  L. Rice,et al.  Controlling Vancomycin-Resistant Enterococci , 1995, Infection Control & Hospital Epidemiology.

[42]  F. Lowy Staphylococcus aureus infections. , 2009, The New England journal of medicine.

[43]  M. Finland,et al.  Methicillin-resistant Staphylococcus aureus at Boston City Hospital. Bacteriologic and epidemiologic observations. , 1968, The New England journal of medicine.

[44]  Arjun Srinivasan,et al.  A clone of methicillin-resistant Staphylococcus aureus among professional football players. , 2005, The New England journal of medicine.

[45]  A. Tomasz,et al.  The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. , 1999, The New England journal of medicine.

[46]  John D. Turnidge,et al.  Dissemination of New Methicillin-Resistant Staphylococcus aureus Clones in the Community , 2002, Journal of Clinical Microbiology.

[47]  D. McClish,et al.  Nosocomial bloodstream infections in United States hospitals: a three-year analysis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[48]  R. Wenzel,et al.  Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[49]  Mian Cai,et al.  Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[50]  L. Rice,et al.  Effect of parenteral antibiotic administration on persistence of vancomycin-resistant Enterococcus faecium in the mouse gastrointestinal tract. , 1999, The Journal of infectious diseases.

[51]  S. McAllister,et al.  Vancomycin-Resistant Staphylococcus aureus Isolate from a Patient in Pennsylvania , 2004, Antimicrobial Agents and Chemotherapy.

[52]  H. Chambers,et al.  The changing epidemiology of Staphylococcus aureus? , 2001, Emerging infectious diseases.

[53]  L. Rice,et al.  Effect of parenteral antibiotic administration on the establishment of colonization with vancomycin-resistant Enterococcus faecium in the mouse gastrointestinal tract. , 2000, The Journal of infectious diseases.

[54]  D. Lauderdale,et al.  Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. , 1998, JAMA.

[55]  M. Marsilio,et al.  Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the Surveillance Network Database--USA. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[56]  A. Schuchat,et al.  Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. , 2003, The New England journal of medicine.

[57]  L. Saravolatz,et al.  Methicillin-resistant Staphylococcus aureus. Epidemiologic observations during a community-acquired outbreak. , 1982, Annals of internal medicine.

[58]  M. Jacobs Streptococcus pneumoniae: epidemiology and patterns of resistance. , 2004, The American journal of medicine.

[59]  W. Martone Spread of Vancomycin-Resistant Enterococci: Why Did It Happen in the United States? , 1998, Infection Control & Hospital Epidemiology.

[60]  F. Vandenesch,et al.  Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[61]  R. Sherertz,et al.  A Cloud Adult: The Staphylococcus aureus-Virus Interaction Revisited , 1996, Annals of Internal Medicine.

[62]  William R Bishai,et al.  Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat. , 2005, The Lancet. Infectious diseases.